Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.

The ROSELLA trial showed relacorilant plus nab-paclitaxel improved progression-free survival in platinum-resistant ovarian cancer patients. Relacorilant reduced disease progression risk by 30% and ...

AbbVie released on March 15 the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum ...

A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and protects replicating DNA in dividing cells. This new structural and ...

For decades, clinical trial sponsors relied on second-hand insights from internal experts, physician perspectives and academia to understand the patient’s point of view. Recently, the research ...

Findings from an earlier trial of the Eli Lilly drug, called lepodisiran, showed the drug was safe. The latest study, a Phase 2 clinical trial funded by Lilly, included 320 people. One injection ...

New data from the phase 3 MIRASOL trial presented at the Society of Gynaecologic Oncology (SGO) Annual Meeting on Women's Cancer in Seattle over the weekend showed that, after more than 30 months ...

Textile weavers, tassel-makers, lighting restorers, cabinet makers and muralists forged new traditions at the sumptuous Beaux-Arts museum. By Patricia Leigh Brown The National Endowment for the ...

The MIRASOL trial (NCT04209855) enrolled 453 patients with platinum-resistant, FRα-positive ovarian cancer who had received 1-3 prior lines of therapy. The patients were randomly assigned to ...